TABLE 3.
Number of reports and reporting odds ratio of pregnancy loss.
| drug | Pregnancy loss | Sensitivity analysis 1: PT “abortion spontaneous” only | Sensitivity analysis 2: Pregnancy loss (restricted to definitive pregnancy-related reports) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Case (n) | Total (n) | ROR [95% CI] | Case (n) | Total (n) | ROR [95% CI] | Case (n) | Total (n) | ROR [95% CI] | |
| Ranibizumab | 19 | 42 | 4.44 [2.42–8.16] | 12 | 42 | 3.38 [1.73–6.61] | 19 | 40 | 5.30 [2.85–9.87] |
| Bevacizumab (intraocular) | 6 | 7 | 32.25 [3.88–267.9] | 6 | 7 | 50.71 [6.11–421.28] | 4 | 5 | 23.44 [2.62–209.77] |
| Aflibercept (intraocular) | 4 | 8 | 5.37 [1.34–21.49] | 2 | 8 | 2.82 [0.57–13.96] | 3 | 7 | 4.40 [0.98–19.64] |
Abbreviations: CI, confidence interval; PT, preferred term; ROR, reporting odds ratio.